Skip to main content

Table 2 SBRT reirradiation for lung cancer

From: Stereotactic body radiation therapy in the re-irradiation situation – a review

Clinical trial Poltinnikov et al. Coon et al. Kelly et al.
No. patients/treatment 17/17 12/12 36/36
Dose 1 st RT course ≥ 50 Gy n/s median 61.5 Gy
  (range, 30–79.2 Gy)
Interval (median) n/s n/s 22.0 months (range, 0–92 months)
Total re-irradiation dose median 32Gy (17.5 – 42.0) 60Gy 50 Gy (72%)
40 Gy (17%)
  Other (11%)
Single fraction dose median 4Gy (2.5 – 4.2) 20Gy 12.5 Gy (72%)
10Gy (17%)
  Other (11%)
Technology SBF Cyberknife SBF, 4D-CT, FDG-PET
Target size median field size 95cm2 (30–189) median GTV 14.3cc Tumor size (median) 1.7cm
(range, 0.6–3.8 cm)
Symptom relief 11/13 n/s n/s
Median follow-up (range) n/s 12 months 15 months (4–45)
Local control 5/17 responders 92% @ 1a 92%
Median Overall survival (range) 5.5 months (2.5–30) 67% @ 1a 59% @ 2a
Toxicity G2 esophagitis n=4 No G3 toxicity At least one G3 in 33% of patients
  G2 pneumonits n=1  
  G3 peunomitis n=7
  G3 esophagitis n=3
  G3 Skin ulcer n=2
  G3 Cough n=1
  No G4/5 toxicities
  1. Abbreviations: RT = radiotherapy; n/s = not specified; SBF = stereotactic body frame; 4D-CT = 4-dimensional computed tomography; FDG-PET = fluorodeoxyglucose positron emission tomography; G = grade; @ = at time of; a = year.